Edition:
United States

Vascular Biogenics Ltd (VBLT.OQ)

VBLT.OQ on NASDAQ Stock Exchange Global Market

2.05USD
10:37am EDT
Change (% chg)

$-0.08 (-3.53%)
Prev Close
$2.12
Open
$2.15
Day's High
$2.15
Day's Low
$2.05
Volume
13,851
Avg. Vol
23,680
52-wk High
$9.05
52-wk Low
$2.05

Chart for

About

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly... (more)

Overall

Beta: -1.73
Market Cap(Mil.): $63.49
Shares Outstanding(Mil.): 29.88
Dividend: --
Yield (%): --

Financials

  VBLT.OQ Industry Sector
P/E (TTM): -- 212.74 32.86
EPS (TTM): -0.44 -- --
ROI: -27.06 -3.73 13.13
ROE: -27.77 -5.79 15.07

BRIEF-Vbl Therapeutics Announces Q1 Loss Per Share $0.24

* VBL THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

May 17 2018

BRIEF-VBL Therapeutics Awarded $2.5 Million Non Dilutive Grant By The Israel Innovation Authority

* VBL THERAPEUTICS AWARDED $2.5 MILLION NON-DILUTIVE GRANT BY THE ISRAEL INNOVATION AUTHORITY Source text for Eikon: Further company coverage:

Apr 09 2018

BRIEF-VBL Therapeutics Announces Top-Line Results From Pivotal Phase 3 Globe Study In Patients With Recurrent Glioblastoma

* VBL THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PIVOTAL PHASE 3 GLOBE STUDY IN PATIENTS WITH RECURRENT GLIOBLASTOMA

Mar 08 2018

BRIEF-VBL Therapeutics Receives Milestone Payment From Nanocarrier Under Licensing Agreement For VB-111 In Japan

* VBL THERAPEUTICS RECEIVES MILESTONE PAYMENT FROM NANOCARRIER UNDER LICENSING AGREEMENT FOR VB-111 IN JAPAN

Feb 08 2018

Earnings vs. Estimates